Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cutia Therapeutics ( (HK:2487) ) has shared an update.
Cutia Therapeutics reported that two key dermatology products, CU-40102 topical finasteride spray and CU-10201 topical 4% minocycline foam, entered commercialization in late October 2025 and generated over RMB100 million in revenue for the year. The Group’s total revenue reached approximately RMB336 million, with second-half revenue surging about 307% to RMB270 million and gross margin improving from 48% to 61%, driven by high-margin products and cost control measures.
Operating efficiency improved notably as selling and distribution, research and development and administrative expenses fell by around RMB109 million year-on-year, reducing the annual loss by approximately RMB94 million. The company closed 2025 with about RMB788 million in cash, time deposits and financial assets, strengthening its financial position as it scales commercialization of its dermatology portfolio and reinforces its competitive standing in China’s broader dermatology treatment and care market.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is an R&D-driven biopharmaceutical company focused on innovative dermatology products, targeting scalp and skin diseases and care, topical anesthesia and localized adipose accumulation management. Founded in 2019, it operates in China’s broader dermatology treatment and care market with fully integrated capabilities spanning demand identification, technology development, clinical trials, manufacturing and marketing, supported by its proprietary CATAME technology platform for advanced topical and transdermal drug delivery.
Average Trading Volume: 327,431
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.63B
For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.